Movement Alert｜Hims & Hers Health Inc. Rises 5.5% in Regular Trading, FDA Advisory Committee Supports Bpc-157 Peptide Compounding Approval

Market Focus07-27

On July 27, Hims & Hers Health Inc. rose 5.5% in regular trading, trading at $29.17/share, with turnover of $79.55 million.

On the news front, the FDA advisory committee recently voted to include the Bpc-157 peptide on the list of substances permitted for pharmacy compounding, delivering a positive regulatory signal. The company had previously actively advocated at panel meetings for the FDA to expand access to specific peptide drugs. This decision is expected to broaden the prescription drug coverage of the company's telehealth platform and create incremental growth opportunities for its GLP-1 weight management business.

Additionally, multiple institutions have recently raised their price targets on the stock. BofA Securities adjusted its target to $36 from $25 while maintaining a neutral rating, and Truist raised its target to $27 from $23, keeping a hold rating. The average analyst price target stands at approximately $30.69 according to FactSet.

Hims & Hers Health Inc. operates a multi-specialty telehealth platform connecting consumers with licensed healthcare professionals across mental health, sexual health, dermatology, and primary care.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165587519?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165587519","market":"us","top_or_hot":-1,"title":"Movement Alert｜Hims & Hers Health Inc. Rises 5.5% in Regular Trading, FDA Advisory Committee Supports Bpc-157 Peptide Compounding Approval","media":"Market Focus","content":"<p><p>On July 27, Hims & Hers Health Inc. rose 5.5% in regular trading, trading at $29.17/share, with turnover of $79.55 million.</p><p>On the news front, the FDA advisory committee recently voted to include the Bpc-157 peptide on the list of substances permitted for pharmacy compounding, delivering a positive regulatory signal. The company had previously actively advocated at panel meetings for the FDA to expand access to specific peptide drugs. This decision is expected to broaden the prescription drug coverage of the company's telehealth platform and create incremental growth opportunities for its GLP-1 weight management business.</p><p>Additionally, multiple institutions have recently raised their price targets on the stock. BofA Securities adjusted its target to $36 from $25 while maintaining a neutral rating, and Truist raised its target to $27 from $23, keeping a hold rating. The average analyst price target stands at approximately $30.69 according to FactSet.</p><p>Hims & Hers Health Inc. operates a multi-specialty telehealth platform connecting consumers with licensed healthcare professionals across mental health, sexual health, dermatology, and primary care.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hims & Hers Health Inc. Rises 5.5% in Regular Trading, FDA Advisory Committee Supports Bpc-157 Peptide Compounding Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hims & Hers Health Inc. Rises 5.5% in Regular Trading, FDA Advisory Committee Supports Bpc-157 Peptide Compounding Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-27 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 27, Hims & Hers Health Inc. rose 5.5% in regular trading, trading at $29.17/share, with turnover of $79.55 million.</p><p>On the news front, the FDA advisory committee recently voted to include the Bpc-157 peptide on the list of substances permitted for pharmacy compounding, delivering a positive regulatory signal. The company had previously actively advocated at panel meetings for the FDA to expand access to specific peptide drugs. This decision is expected to broaden the prescription drug coverage of the company's telehealth platform and create incremental growth opportunities for its GLP-1 weight management business.</p><p>Additionally, multiple institutions have recently raised their price targets on the stock. BofA Securities adjusted its target to $36 from $25 while maintaining a neutral rating, and Truist raised its target to $27 from $23, keeping a hold rating. The average analyst price target stands at approximately $30.69 according to FactSet.</p><p>Hims & Hers Health Inc. operates a multi-specialty telehealth platform connecting consumers with licensed healthcare professionals across mental health, sexual health, dermatology, and primary care.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1165587519","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165587519","pubTimestamp":1785160502,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 27, Hims & Hers Health Inc. rose 5.5% in regular trading, trading at $29.17/share, with turnover of $79.55 million.On the news front, the FDA advisory committee recently voted to include the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"动态警报|Hims & Hers Health Inc. 常规交易上涨 5.5%，FDA 咨询委员会支持 Bpc-157 肽复合批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"On July 27, Hims & Hers Health Inc. rose 5.5% in regular trading, trading at $29.17/share, with turnover of $79.55 million.On the news front, the FDA advisory committee recently voted to include the Bpc-157 peptide on the list of substances permitted for pharmacy compounding, delivering a positive regulatory signal. The company had previously actively advocated at panel meetings for the FDA to expand access to specific peptide drugs. This decision is expected to broaden the prescription drug coverage of the company's telehealth platform and create incremental growth opportunities for its GLP-1 weight management business.Additionally, multiple institutions have recently raised their price targets on the stock. BofA Securities adjusted its target to $36 from $25 while maintaining a neutral rating, and Truist raised its target to $27 from $23, keeping a hold rating. The average analyst price target stands at approximately $30.69 according to FactSet.Hims & Hers Health Inc. operates a multi-specialty telehealth platform connecting consumers with licensed healthcare professionals across mental health, sexual health, dermatology, and primary care.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165587519","isCrawlerRequest":true}